ES2186811T3 - Derivados de feniltiazol con propiedades anti-virus herpes. - Google Patents

Derivados de feniltiazol con propiedades anti-virus herpes.

Info

Publication number
ES2186811T3
ES2186811T3 ES96945567T ES96945567T ES2186811T3 ES 2186811 T3 ES2186811 T3 ES 2186811T3 ES 96945567 T ES96945567 T ES 96945567T ES 96945567 T ES96945567 T ES 96945567T ES 2186811 T3 ES2186811 T3 ES 2186811T3
Authority
ES
Spain
Prior art keywords
herpes
derivatives
phenyltiazol
properties
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945567T
Other languages
English (en)
Inventor
James J Crute
Anne-Marie Fauche
Christopher A Grygon
Karl D Hargrave
Bruno Simoneau
Bounkham Thavonekham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Canada Ltd
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Canada Ltd, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Canada Ltd
Application granted granted Critical
Publication of ES2186811T3 publication Critical patent/ES2186811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE A METODOS PARA INHIBIR LA REPLICACION DE HERPES Y PARA TRATAR INFECCIONES POR HERPES EN UN MAMIFERO MEDIANTE INHIBICION DEL COMPLEJO ENZIMATICO HELICASA-PRIMASA DEL HERPES. ESTA INVENCION TAMBIEN SE REFIERE A DERIVADOS TIAZOLILFENILO DE FORMULA (G) QUE INHIBEN EL COMPLEJO HELICASAPRIMASA DEL HERPES Y A COMPOSICIONES FARMACEUTICAS QUE INCLUYEN LOS DERIVADOS TIAZOLILFENILO, A METODOS PARA USAR Y METODOS PARA PRODUCIR LOS DERIVADOS TIAZOLILFENILO. EN LA FORMULA (G), R Y Z SON COMO SE DEFINE EN LA APLICACION EN LA QUE Z ES EL RASGO CARACTERISTICO.
ES96945567T 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes. Expired - Lifetime ES2186811T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US943395P 1995-12-29 1995-12-29
US2320996P 1996-08-02 1996-08-02

Publications (1)

Publication Number Publication Date
ES2186811T3 true ES2186811T3 (es) 2003-05-16

Family

ID=26679472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945567T Expired - Lifetime ES2186811T3 (es) 1995-12-29 1996-12-04 Derivados de feniltiazol con propiedades anti-virus herpes.

Country Status (26)

Country Link
US (3) US6057451A (es)
EP (1) EP0871619B1 (es)
JP (1) JP4327249B2 (es)
KR (1) KR19990076964A (es)
AR (1) AR037060A1 (es)
AT (1) ATE227279T1 (es)
AU (1) AU1682897A (es)
BG (1) BG102583A (es)
BR (1) BR9612435A (es)
CA (1) CA2192433C (es)
CZ (1) CZ207298A3 (es)
DE (1) DE69624728T2 (es)
DK (1) DK0871619T3 (es)
EA (1) EA199800611A1 (es)
EE (1) EE9800154A (es)
ES (1) ES2186811T3 (es)
HU (1) HUP9902341A2 (es)
IL (1) IL124436A0 (es)
MX (1) MX9805291A (es)
NO (1) NO982950D0 (es)
NZ (1) NZ331104A (es)
PL (1) PL327582A1 (es)
PT (1) PT871619E (es)
SK (1) SK89398A3 (es)
TR (1) TR199801244T2 (es)
WO (1) WO1997024343A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
JP2002528533A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー 酵素ｉｍｐｄｈの新規なインヒビター
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
US6166028A (en) 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
JP2002539119A (ja) * 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
MXPA02000253A (es) 1999-07-01 2002-06-21 Ajinomoto Kk Compuestos heterociclicos y uso medico de los mismos.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
WO2001096874A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE60120421T2 (de) * 2000-08-21 2006-12-28 Pacific Corp. Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
WO2002016317A1 (en) * 2000-08-21 2002-02-28 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
WO2002016318A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
CN1473157A (zh) * 2000-11-10 2004-02-04 ֮����ҩ��ʽ���� 酰胺衍生物
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
AU2003225971A1 (en) * 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
WO2003095435A1 (en) * 2002-05-09 2003-11-20 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives
CA2503844A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
CA2514573A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
CN100491361C (zh) 2003-01-27 2009-05-27 安斯泰来制药有限公司 噻唑衍生物及其作为vap-1抑制剂的用途
KR20120045062A (ko) * 2003-03-31 2012-05-08 가부시키가이샤 아루떼꾸 우에노 혈관 과투과 질환의 치료방법
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
EP2275445A3 (en) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
JP5011739B2 (ja) * 2005-02-03 2012-08-29 アステラス製薬株式会社 テトラヒドロ−２ｈ−チオピラン−４−カルボキサミド誘導体を含有する医薬組成物
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US20070021434A1 (en) * 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2661863A1 (en) * 2006-08-30 2008-03-06 F. Hoffmann-La Roche Ag Inhibitors for glyt-1
US20090317360A1 (en) * 2007-06-12 2009-12-24 Genelabs Technologies, Inc. Anti-viral inhibitors and methods of use
JPWO2010047295A1 (ja) 2008-10-20 2012-03-22 アステラス製薬株式会社 帯状疱疹関連痛の予防又は治療薬
JP5583694B2 (ja) * 2009-01-05 2014-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するピロリジン化合物
US8822515B2 (en) 2009-10-16 2014-09-02 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
WO2012113920A1 (en) 2011-02-24 2012-08-30 Katholieke Universiteit Leuven Arylsulfone derivatives with activity against human betaherpesviruses
KR101399484B1 (ko) * 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
UY35772A (es) 2013-10-14 2015-05-29 Bayer Cropscience Ag Nuevos compuestos plaguicidas
CA2967316C (en) 2014-11-10 2021-12-14 Forge Life Science, Llc Anti-hcmv compositions and methods
EP3256461B1 (en) * 2015-02-13 2023-09-13 Azienda Ospedaliera Universitaria Senese Urea and sulfonamide derivatives as human helicase ddx3 inhibitors useful in the treatment of viral diseases
GEP20207128B (en) 2016-04-06 2020-07-10 Molecules Gm Innovative Aminothiazole derivatives useful as antiviral agents
WO2018132372A1 (en) 2017-01-10 2018-07-19 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
DK3692039T3 (da) 2017-10-05 2023-03-13 Innovative Molecules Gmbh Enantiomerer af substituerede thiazoler som antivirale forbindelser
JP7399122B2 (ja) 2018-07-05 2023-12-15 サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート ウレア構造を有する縮合環化合物
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
CN113164448A (zh) * 2018-12-19 2021-07-23 利奥制药有限公司 作为il-17的小分子调节剂的氨基酸苯胺类化合物
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
CA3265860A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions against the herpes virus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629247A (en) * 1969-06-06 1971-12-21 Pfizer Thiazoline and 5 6-dihydro-4h-1 3-thiazine antiviral agents
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants
JPH075579B2 (ja) * 1986-09-01 1995-01-25 吉富製薬株式会社 アミノチアゾ−ル化合物
MX174210B (es) * 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
HU207310B (en) * 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
AU1347292A (en) * 1991-01-18 1992-08-27 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression of viral genes and other genes
GB9125970D0 (en) * 1991-12-06 1992-02-05 Fujisawa Pharmaceutical Co New compounds
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
GB2276164A (en) * 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
CA2190870A1 (en) * 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
AU3289299A (en) * 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents

Also Published As

Publication number Publication date
EP0871619A1 (en) 1998-10-21
TR199801244T2 (xx) 1998-12-21
US6458959B1 (en) 2002-10-01
EP0871619B1 (en) 2002-11-06
US6057451A (en) 2000-05-02
DK0871619T3 (da) 2003-03-03
PT871619E (pt) 2003-03-31
WO1997024343A1 (en) 1997-07-10
CA2192433C (en) 2008-01-08
JP4327249B2 (ja) 2009-09-09
CZ207298A3 (cs) 1998-11-11
SK89398A3 (en) 1998-11-04
CA2192433A1 (en) 1997-06-30
DE69624728D1 (de) 2002-12-12
NZ331104A (en) 2000-03-27
NO982950L (no) 1998-06-25
US6348477B1 (en) 2002-02-19
DE69624728T2 (de) 2003-07-10
BR9612435A (pt) 1999-07-13
ATE227279T1 (de) 2002-11-15
NO982950D0 (no) 1998-06-25
PL327582A1 (en) 1998-12-21
HUP9902341A2 (hu) 1999-10-28
AU1682897A (en) 1997-07-28
JP2000502702A (ja) 2000-03-07
IL124436A0 (en) 1998-12-06
AR037060A1 (es) 2004-10-20
KR19990076964A (ko) 1999-10-25
EA199800611A1 (ru) 1999-04-29
MX9805291A (es) 1998-10-31
BG102583A (bg) 1999-06-30
EE9800154A (et) 1998-12-15

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CR20250500A (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
BR0213129A (pt) Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
MX9304359A (es) Derivados de rapamicina.
ES2183937T3 (es) Inhibidores de la adhesion celular.
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
DOP2009000272A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit
BG102583A (bg) Фенилтиазолови производни с антихерпесвирусни свойства
MX9304361A (es) Derivados de rapamicina.
UY25780A1 (es) Nuevos antibióticos macrólidos
UY40701A (es) Protacs para irak4
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
MX2020011367A (es) Compuesto oxo-sustituido.
HN1997000070A (es) Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos
ECSP014079A (es) Derivados de sulfonamida